encephalitis

Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html

---

Study Counts

Type	Study_count
Total_Studies	164
interventional	136
Observational	26
Registry	2

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type	Study_Count
Biological	83
Drug	14
Biological|placebo	8
Drug|placebo	6
Device	5
Other	5
Biological|Other	3
Drug|Other	3
Procedure	2
Behavioral	1
Biological|Drug|Other|Procedure	1
Biological|Procedure	1
Combination Product	1
Diagnostic Test	1
Dietary Supplement	1
Drug|Procedure	1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country	Study_Count
United States	26
NA	12
Germany	8
Austria	7
Austria|Germany	6
Philippines	6
Poland	6
Thailand	6
China	5
Korea, Republic of	5
Vietnam	5
United Kingdom	4
Australia	3
Austria|Germany|Poland	3
United States|Canada	3
Belgium	2
France	2
India	2
Philippines|Thailand	2
Russian Federation	2
Slovenia	2
Sri Lanka	2
Taiwan	2
United States|Australia	2
Austria|Czech Republic	1
Austria|Germany|Switzerland	1
Bangladesh	1
Czech Republic	1
Czech Republic|Germany	1
Czechia	1
Finland	1
Finland|Sweden	1
Nepal	1
Singapore	1
United States|Australia|Denmark|Germany|Sweden	1
United States|Australia|Germany	1
United States|Canada|Sweden|United Kingdom	1

Sites per Study

Site_count	Study_Count
1	71
2	14
3	13
4	6
5	3
6	2
7	3
8	7
9	1
10	4
13	1
16	2
19	1
21	1
22	2
23	2
25	2
69	1

Phase

Phase	Study_Count
Phase 3	40
Phase 4	33
Phase 2	27
N/A	21
Phase 1	10
Phase 1/Phase 2	2
Phase 2/Phase 3	2
Early Phase 1	1

Number of Arms

Number_of_Arms	Count_of_Studies
1	27
2	42
3	21
4	13
5	3
6	3
NA	27

Enrollment Metrics by Phase

Measure	Early.Phase.1	N.A	Phase.1	Phase.1.Phase.2	Phase.2	Phase.2.Phase.3	Phase.3	Phase.4
Min.	144	7.00000	10.00	22	22.0	200	23.0000	17.0000
1st Qu.	144	40.00000	22.00	32	50.0	200	262.0000	70.0000
Median	144	60.00000	29.00	42	100.0	200	389.0000	206.0000
Mean	144	96.89474	31.90	42	164.6	200	745.0256	575.1935
3rd Qu.	144	85.00000	44.25	52	200.0	200	740.5000	331.5000
Max.	144	600.00000	56.00	62	615.0	200	3973.0000	10000.0000

Trial Group Type

group_type	Group_Count
Experimental	140
Active Comparator	80
NA	27
Placebo Comparator	18
Other	16
Sham Comparator	3
No Intervention	2

Intervention Model

intervention_model	Study_Count
Parallel Assignment	81
Single Group Assignment	42
Crossover Assignment	5
NA	4
Factorial Assignment	2
Sequential Assignment	2

Primary Purpose

primary_purpose	Study_Count
Prevention	90
Treatment	28
Basic Science	7
NA	6
Diagnostic	3
Health Services Research	1
Other	1

Observational Studies

Studies by Country

Country	Study_Count
France	7
United States	6
NA	2
Austria	1
Canada	1
China	1
Denmark	1
Germany|Italy|United Kingdom	1
Korea, Republic of	1
Netherlands	1
Slovenia	1
Sweden	1
Switzerland	1
United Kingdom	1

Sites per Study

Site_count	Study_Count
1	21
4	1
7	2
8	1
22	1

Enrollment Metrics

Measure	Observational
Min	5.00
1st Qu	50.00
Median	100.00
Mean	1244.84
3rd Qu	690.00
Max	20000.00

Observation Model

observational_model	Study_Count
Cohort	15
NA	4
Case-Only	3
Other	3
Case-Control	1

Time Perspective

time_perspective	Study_Count
Prospective	11
Retrospective	9
NA	4
Cross-Sectional	1
Other	1

Registries

Studies by Country

Country	Study_Count
Cambodia|Lao People’s Democratic Republic|Myanmar|Vietnam	1
Colombia	1

Sites per Study

Site_count	Study_Count
7	1
8	1

Enrollment Metrics

Measure	Registries
Min	570.0
1st Qu	627.5
Median	685.0
Mean	685.0
3rd Qu	742.5
Max	800.0

Registry Model

observational_model	Study_Count
Case-Control	1
Cohort	1

Time Perspective

time_perspective	Study_Count
Prospective	2

Follow-up

target_duration	Study_Count
1 Year	1
4 Weeks	1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id	brief_title	link	overall_status	source	primary_completion_date
NCT03662750	TSPO PET as a Measure of Post-stroke Brain Inflammation: a Natural History Cohort	https://ClinicalTrials.gov/show/NCT03662750	Recruiting	Imperial College London	2019-12-31
NCT03826056	Neurology Inpatient Clinical Education Trial	https://ClinicalTrials.gov/show/NCT03826056	Active, not recruiting	Dartmouth-Hitchcock Medical Center	2020-10-31
NCT03282370	Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam	https://ClinicalTrials.gov/show/NCT03282370	Completed	National Institute of Hygiene and Epidemiology, Vietnam	2018-02-06
NCT03204227	Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age	https://ClinicalTrials.gov/show/NCT03204227	Completed	National Institute of Hygiene and Epidemiology, Vietnam	2017-08-12
NCT03194815	IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2	https://ClinicalTrials.gov/show/NCT03194815	Recruiting	University of Cambridge	2020-12-31
NCT03181945	Duration of Anti-convulsant Therapy for Acute Symptomatic Seizure in Acute Encephalitis Syndrome	https://ClinicalTrials.gov/show/NCT03181945	Active, not recruiting	Postgraduate Institute of Medical Education and Research	2018-09-30
NCT02910037	Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort	https://ClinicalTrials.gov/show/NCT02910037	Completed	University of California, San Francisco	2017-07-31
NCT02816554	Safety and Immunogenicity of JECEVAX in Young Children	https://ClinicalTrials.gov/show/NCT02816554	Completed	National Institute of Hygiene and Epidemiology, Vietnam	2015-09-30
NCT02654509	Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine	https://ClinicalTrials.gov/show/NCT02654509	Completed	U.S. Army Medical Research and Development Command	2016-02-16
NCT02643433	Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines	https://ClinicalTrials.gov/show/NCT02643433	Completed	Centers for Disease Control and Prevention, China	2016-06-30
NCT02602652	Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine	https://ClinicalTrials.gov/show/NCT02602652	Completed	Chulalongkorn University	2015-07-31
NCT02233868	Brain Inflammation and Function in Alcoholism	https://ClinicalTrials.gov/show/NCT02233868	Recruiting	National Institutes of Health Clinical Center (CC)	2024-12-31
NCT02538094	tDCS and Cognition in Adults With Multiple Sclerosis or Encephalitis	https://ClinicalTrials.gov/show/NCT02538094	Completed	Johns Hopkins University	2019-06-30
NCT02532569	Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj	https://ClinicalTrials.gov/show/NCT02532569	Completed	Boryung Pharmaceutical Co., Ltd	2016-10-31
NCT02526550	Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX	https://ClinicalTrials.gov/show/NCT02526550	Completed	Siriraj Hospital	2014-07-31
NCT02514746	Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose	https://ClinicalTrials.gov/show/NCT02514746	Completed	PATH	2016-12-15
NCT02511535	TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients	https://ClinicalTrials.gov/show/NCT02511535	Completed	Medical University of Vienna	2016-02-29
NCT02492165	Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects	https://ClinicalTrials.gov/show/NCT02492165	Completed	Sanofi	2016-03-31
NCT02479698	Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus	https://ClinicalTrials.gov/show/NCT02479698	Recruiting	M.D. Anderson Cancer Center	2020-07-31
NCT02463942	Tick-borne Encephalitis and Positive Borrelial Antibodies	https://ClinicalTrials.gov/show/NCT02463942	Recruiting	University Medical Centre Ljubljana	2020-09-30
NCT02367664	A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants	https://ClinicalTrials.gov/show/NCT02367664	Completed	Jiangsu Province Centers for Disease Control and Prevention	2016-06-30
NCT02308982	Investigating the Role of Early Intravenous Immunoglobulin Treatment for Children With Encephalitis	https://ClinicalTrials.gov/show/NCT02308982	Active, not recruiting	University of Oxford	2019-02-28
NCT02186626	Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age	https://ClinicalTrials.gov/show/NCT02186626	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	2016-07-31
NCT01296360	Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country	https://ClinicalTrials.gov/show/NCT01296360	Completed	Valneva Austria GmbH	2011-11-30
NCT02039440	6-year Antibody Check After Third Vaccination Against Japanese Encephalitis	https://ClinicalTrials.gov/show/NCT02039440	Completed	Medical University of Vienna	2014-06-30
NCT01991067	Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients	https://ClinicalTrials.gov/show/NCT01991067	Completed	Medical University of Vienna	2018-10-28
NCT01984983	Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers	https://ClinicalTrials.gov/show/NCT01984983	Completed	Ichor Medical Systems Incorporated	2014-06-30
NCT01981967	Post-licensure Safety Study of IMOJEV® in Thailand	https://ClinicalTrials.gov/show/NCT01981967	Completed	Sanofi	2015-04-30
NCT01943305	The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans	https://ClinicalTrials.gov/show/NCT01943305	Completed	Singapore General Hospital	2015-06-30
NCT01900444	Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea	https://ClinicalTrials.gov/show/NCT01900444	Completed	Sanofi	2014-03-11
NCT01856205	Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis	https://ClinicalTrials.gov/show/NCT01856205	Completed	University of Liverpool	2009-08-31
NCT01815073	Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine	https://ClinicalTrials.gov/show/NCT01815073	Completed	Changchun Keygen Biological Products Co., Ltd.	2013-07-31
NCT01662440	Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects	https://ClinicalTrials.gov/show/NCT01662440	Completed	Novartis	2012-12-31
NCT01656200	A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2	https://ClinicalTrials.gov/show/NCT01656200	Completed	Indian Institute of Science	2013-10-31
NCT01582698	TBE Seropersistence up to 10 Years After First Booster in Adults	https://ClinicalTrials.gov/show/NCT01582698	Completed	Baxter Healthcare Corporation	2015-06-30
NCT01567865	Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine	https://ClinicalTrials.gov/show/NCT01567865	Completed	PATH	2012-12-31
NCT01562444	Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules	https://ClinicalTrials.gov/show/NCT01562444	Completed	GlaxoSmithKline	2016-09-30
NCT01466387	A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults	https://ClinicalTrials.gov/show/NCT01466387	Completed	Novartis	2012-04-30
NCT01408537	Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children	https://ClinicalTrials.gov/show/NCT01408537	Completed	Mahidol University	2012-10-31
NCT01398540	Cellular and Humoral Immunity in Elderly After Immunization With a Japanese Encephalitis Vaccine	https://ClinicalTrials.gov/show/NCT01398540	Completed	Medical University of Vienna	2012-10-31
NCT01396512	Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEVâ„¢) Compared to CD.JEVAXâ„¢ in Toddlers	https://ClinicalTrials.gov/show/NCT01396512	Completed	Sanofi	2013-03-31
NCT01386827	Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese Encephalitis	https://ClinicalTrials.gov/show/NCT01386827	Completed	Helsinki University Central Hospital	2011-04-30
NCT01361776	Humoral Response to Tick-borne Encephalitis Vaccine in Elderly	https://ClinicalTrials.gov/show/NCT01361776	Completed	Sormland County Council, Sweden	2013-12-31
NCT04361344	Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection	https://ClinicalTrials.gov/show/NCT04361344	Recruiting	Centre Hospitalier de PAU	2021-01-19
NCT04344626	Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery	https://ClinicalTrials.gov/show/NCT04344626	Recruiting	University of California, Los Angeles	2023-03-31
NCT04343469	Effects of Morbid Obesity and Bariatric Surgery on Brain Inflammation, and Activation of Central Reward System	https://ClinicalTrials.gov/show/NCT04343469	Recruiting	Turku University Hospital	2022-09-30
NCT04325685	The Effect of Supraglottic and Oropharyngeal Decontamination on the Incidence of Ventilator-associated Pneumonia	https://ClinicalTrials.gov/show/NCT04325685	Active, not recruiting	Northern State Medical University	2021-12-31
NCT04323150	The Effect of Closed Suction System on the Incidence of Ventilator-associated Pneumonia.	https://ClinicalTrials.gov/show/NCT04323150	Recruiting	Northern State Medical University	2020-12-31
NCT04223037	Purified Inactivated Japanese Encephalitis Vaccine	https://ClinicalTrials.gov/show/NCT04223037	Active, not recruiting	Chinese Academy of Medical Sciences	2018-03-07
NCT04137159	An Exercise Intervention to Reduce Neuropathic Pain and Brain Inflammation After Spinal Cord Injury	https://ClinicalTrials.gov/show/NCT04137159	Recruiting	Spaulding Rehabilitation Hospital	2025-01-31
NCT04131595	Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects	https://ClinicalTrials.gov/show/NCT04131595	Active, not recruiting	Bavarian Nordic	2020-06-30
NCT04080921	Stem Cell Transplantation In-patient With Neurological Sequelae Due to Encephalitis or Meningitis	https://ClinicalTrials.gov/show/NCT04080921	Completed	Vinmec Research Institute of Stem Cell and Gene Technology	2019-06-30
NCT04017052	Application of a TBE-Vaccine in Obese Persons	https://ClinicalTrials.gov/show/NCT04017052	Active, not recruiting	Medical University of Vienna	2020-02-07
NCT04002219	Efficacy Evaluation of the Mushroom Beverage on Emotion Regulation	https://ClinicalTrials.gov/show/NCT04002219	Recruiting	National Science Council, Taiwan	2019-12-31
NCT03993262	Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis	https://ClinicalTrials.gov/show/NCT03993262	Recruiting	Jena University Hospital	2022-07-01
NCT03971058	Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals.	https://ClinicalTrials.gov/show/NCT03971058	Recruiting	Medical University of Vienna	2020-12-31
NCT03956446	Tick-borne Encephalitis and Borrelial Antibodies in Serum	https://ClinicalTrials.gov/show/NCT03956446	Recruiting	University Medical Centre Ljubljana	2020-12-31
NCT03879603	VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults	https://ClinicalTrials.gov/show/NCT03879603	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	2020-02-26
NCT03835728	Efficacy of Ocrelizumab in Autoimmune Encephalitis	https://ClinicalTrials.gov/show/NCT03835728	Recruiting	University of Texas Southwestern Medical Center	2022-01-22
NCT03776994	Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine	https://ClinicalTrials.gov/show/NCT03776994	Active, not recruiting	SRI International	2020-07-31
NCT03542279	Immunotherapy in Autoimmune Encephalitis	https://ClinicalTrials.gov/show/NCT03542279	Recruiting	Xuanwu Hospital, Beijing	2021-12-31
NCT03435861	Effect of Neflamapimod on Brain Inflammation in Alzheimer’s Disease Patients	https://ClinicalTrials.gov/show/NCT03435861	Recruiting	University Hospital, Toulouse	2020-01-30
NCT01246479	Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study	https://ClinicalTrials.gov/show/NCT01246479	Completed	Valneva Austria GmbH	2012-10-31
NCT01190228	Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV	https://ClinicalTrials.gov/show/NCT01190228	Completed	Sanofi	2010-10-29
NCT01188343	Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers	https://ClinicalTrials.gov/show/NCT01188343	Completed	Sanofi	2012-07-31
NCT01159561	Western Equine Encephalitis Vaccine, Inactivated	https://ClinicalTrials.gov/show/NCT01159561	Completed	U.S. Army Medical Research and Development Command	2011-08-31
NCT01158599	This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population	https://ClinicalTrials.gov/show/NCT01158599	Completed	Valneva Austria GmbH	2011-06-30
NCT01150942	Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea	https://ClinicalTrials.gov/show/NCT01150942	Completed	Boryung Pharmaceutical Co., Ltd	2012-09-30
NCT01106482	An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE	https://ClinicalTrials.gov/show/NCT01106482	Completed	Novartis	2011-05-31
NCT01092507	A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers	https://ClinicalTrials.gov/show/NCT01092507	Completed	Sanofi	2011-09-30
NCT01041573	Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population	https://ClinicalTrials.gov/show/NCT01041573	Completed	Valneva Austria GmbH	2011-02-28
NCT01001988	Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers	https://ClinicalTrials.gov/show/NCT01001988	Completed	Sanofi	2013-10-16
NCT00982137	Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)	https://ClinicalTrials.gov/show/NCT00982137	Completed	Sanofi	2005-04-30
NCT00981630	Study of Live Attenuated ChimeriVaxâ„¢-Japanese Encephalitis Vaccine	https://ClinicalTrials.gov/show/NCT00981630	Completed	Sanofi	2006-02-28
NCT00981175	A Study of ChimeriVaxâ„¢-JE Live Attenuated Vaccine in Healthy Adults	https://ClinicalTrials.gov/show/NCT00981175	Completed	Sanofi	2004-06-30
NCT00894686	Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)	https://ClinicalTrials.gov/show/NCT00894686	Completed	Pfizer	2017-05-10
NCT00840801	Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children	https://ClinicalTrials.gov/show/NCT00840801	Completed	Pfizer	2009-05-31
NCT02880865	Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine	https://ClinicalTrials.gov/show/NCT02880865	Completed	PATH	2017-05-19
NCT01865578	Transcranial Direct Current Stimulation on Cortical Plasticity in Patients With Anti-NMDA Receptor Encephalitis	https://ClinicalTrials.gov/show/NCT01865578	Completed	Charite University, Berlin, Germany	2015-05-31
NCT01710189	Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac	https://ClinicalTrials.gov/show/NCT01710189	Completed	University of Surrey	2014-10-31
NCT00804219	Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination	https://ClinicalTrials.gov/show/NCT00804219	Completed	Medical University of Vienna	2010-11-30
NCT01047839	Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries	https://ClinicalTrials.gov/show/NCT01047839	Completed	Valneva Austria GmbH	2013-08-31
NCT02466750	Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine	https://ClinicalTrials.gov/show/NCT02466750	Recruiting	U.S. Army Medical Research and Development Command	2020-06-30
NCT04175522	Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:	https://ClinicalTrials.gov/show/NCT04175522	Completed	Green Cross Corporation	2020-06-11
NCT00776230	Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling	https://ClinicalTrials.gov/show/NCT00776230	Completed	Valneva Austria GmbH	2010-06-30
NCT00735644	Study of ChimeriVaxâ„¢-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines	https://ClinicalTrials.gov/show/NCT00735644	Completed	Sanofi	2009-05-31
NCT00716066	Autologous Peripheral Blood Stem Cell Transplant for Neurologic Autoimmune Diseases	https://ClinicalTrials.gov/show/NCT00716066	Recruiting	Fred Hutchinson Cancer Research Center	2026-03-31
NCT00694460	Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers	https://ClinicalTrials.gov/show/NCT00694460	Completed	Novartis	2004-08-31
NCT00621764	Immunogenicity and Safety of ChimeriVaxâ„¢ Japanese Encephalitis Vaccine in Thai Toddlers and Children	https://ClinicalTrials.gov/show/NCT00621764	Completed	Sanofi	2009-12-31
NCT00605085	Safety and Tolerability of the Japanese Encephalitis Vaccine IC51	https://ClinicalTrials.gov/show/NCT00605085	Completed	Valneva Austria GmbH	NA
NCT00604708	Immunogenicity Study of the Japanese Encephalitis Vaccine IC51	https://ClinicalTrials.gov/show/NCT00604708	Completed	Valneva Austria GmbH	2006-09-30
NCT00596271	Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440	https://ClinicalTrials.gov/show/NCT00596271	Completed	Valneva Austria GmbH	2006-07-31
NCT00595790	Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51	https://ClinicalTrials.gov/show/NCT00595790	Completed	Valneva Austria GmbH	2006-02-28
NCT00595465	Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51	https://ClinicalTrials.gov/show/NCT00595465	Completed	Valneva Austria GmbH	2008-02-29
NCT00595309	Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51	https://ClinicalTrials.gov/show/NCT00595309	Completed	Valneva Austria GmbH	2009-10-31
NCT00595270	Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51	https://ClinicalTrials.gov/show/NCT00595270	Completed	Valneva Austria GmbH	2007-09-30
NCT00594958	Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51	https://ClinicalTrials.gov/show/NCT00594958	Completed	Valneva Austria GmbH	2007-04-30
NCT00584805	Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine	https://ClinicalTrials.gov/show/NCT00584805	Completed	U.S. Army Medical Research and Development Command	2016-06-27
NCT00503529	TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)	https://ClinicalTrials.gov/show/NCT00503529	Completed	Pfizer	2010-07-31
NCT00463684	Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age	https://ClinicalTrials.gov/show/NCT00463684	Completed	PATH	2007-11-07
NCT00463476	Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine	https://ClinicalTrials.gov/show/NCT00463476	Completed	PATH	2007-11-01
NCT00460486	Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule	https://ClinicalTrials.gov/show/NCT00460486	Completed	Pfizer	2007-11-30
NCT00452621	Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years	https://ClinicalTrials.gov/show/NCT00452621	Completed	Novartis	NA
NCT00441259	Safety and Efficacy Study of ChimeriVaxâ„¢-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age	https://ClinicalTrials.gov/show/NCT00441259	Completed	Sanofi	2011-02-28
NCT00412516	Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine	https://ClinicalTrials.gov/show/NCT00412516	Completed	PATH	2010-03-31
NCT00387634	Safety and Long-term Evaluation (up to 5 Years) of First Booster Immunization With Novartis’ TBE Vaccine for Adults in Adolescents and Adults	https://ClinicalTrials.gov/show/NCT00387634	Completed	Novartis	2011-10-31
NCT00381433	Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid	https://ClinicalTrials.gov/show/NCT00381433	Completed	Sarepta Therapeutics, Inc.	2006-10-31
NCT00367081	Treatment of Cerebral Toxoplasmosis in HIV/AIDS	https://ClinicalTrials.gov/show/NCT00367081	Completed	Rajavithi Hospital	NA
NCT00319592	A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX	https://ClinicalTrials.gov/show/NCT00319592	Completed	Sanofi	2006-09-30
NCT00314145	A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxâ„¢-JE and JE-VAX	https://ClinicalTrials.gov/show/NCT00314145	Completed	Sanofi	2006-06-30
NCT00314132	Safety Study of ChimeriVaxâ„¢-JE Vaccine to Prevent Japanese Encephalitis.	https://ClinicalTrials.gov/show/NCT00314132	Completed	Sanofi	2006-11-30
NCT00311493	Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults	https://ClinicalTrials.gov/show/NCT00311493	Completed	Novartis	NA
NCT00311441	Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children	https://ClinicalTrials.gov/show/NCT00311441	Completed	Novartis	NA
NCT00259805	A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal Encephalitis	https://ClinicalTrials.gov/show/NCT00259805	Completed	California Pacific Medical Center Research Institute	2008-12-31
NCT00249769	Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine	https://ClinicalTrials.gov/show/NCT00249769	Completed	PATH	2006-05-30
NCT00163540	Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)	https://ClinicalTrials.gov/show/NCT00163540	Completed	Pfizer	NA
NCT00161967	TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)	https://ClinicalTrials.gov/show/NCT00161967	Completed	Pfizer	2008-07-31
NCT00161954	Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years	https://ClinicalTrials.gov/show/NCT00161954	Completed	Pfizer	NA
NCT00161889	FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years	https://ClinicalTrials.gov/show/NCT00161889	Completed	Pfizer	NA
NCT00161876	FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years	https://ClinicalTrials.gov/show/NCT00161876	Completed	Pfizer	NA
NCT00161863	Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years	https://ClinicalTrials.gov/show/NCT00161863	Completed	Pfizer	NA
NCT00161850	FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years	https://ClinicalTrials.gov/show/NCT00161850	Completed	Pfizer	NA
NCT00161824	Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR	https://ClinicalTrials.gov/show/NCT00161824	Completed	Pfizer	NA
NCT00161798	Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.	https://ClinicalTrials.gov/show/NCT00161798	Completed	Pfizer	NA
NCT00161785	Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years	https://ClinicalTrials.gov/show/NCT00161785	Completed	Pfizer	NA
NCT00161772	Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.	https://ClinicalTrials.gov/show/NCT00161772	Completed	Pfizer	NA
NCT00161746	Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years	https://ClinicalTrials.gov/show/NCT00161746	Completed	Pfizer	NA
NCT00118924	Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults	https://ClinicalTrials.gov/show/NCT00118924	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	2007-07-31
NCT00094718	Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3’delta30) in Healthy Adults	https://ClinicalTrials.gov/show/NCT00094718	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	2005-04-30
NCT00068055	IVIG - West Nile Encephalitis: Safety and Efficacy	https://ClinicalTrials.gov/show/NCT00068055	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	2006-12-31
NCT00031486	Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir	https://ClinicalTrials.gov/show/NCT00031486	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	2010-06-30
NCT00002064	Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse	https://ClinicalTrials.gov/show/NCT00002064	Completed	NIH AIDS Clinical Trials Information Service	NA
NCT00001994	A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine	https://ClinicalTrials.gov/show/NCT00001994	Completed	NIH AIDS Clinical Trials Information Service	NA
NCT00000794	Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis	https://ClinicalTrials.gov/show/NCT00000794	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	NA
NCT00000674	A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS	https://ClinicalTrials.gov/show/NCT00000674	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	NA
NCT00000666	A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection	https://ClinicalTrials.gov/show/NCT00000666	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	NA

Observational Studiess

#If less then 500 studies

nct_id	brief_title	link	overall_status	source	primary_completion_date
NCT04460599	Neurological Features of SARS COV 2 Infection	https://ClinicalTrials.gov/show/NCT04460599	Recruiting	Centre d’Investigation Clinique et Technologique 805	2020-07-30
NCT03418441	Central Nervous System Infections in Denmark	https://ClinicalTrials.gov/show/NCT03418441	Recruiting	Aalborg University Hospital	2025-01-01
NCT03242395	PRIME: Cognitive Outcome Following Major Burns	https://ClinicalTrials.gov/show/NCT03242395	Completed	Chelsea and Westminster NHS Foundation Trust	2017-02-28
NCT03027232	Control of Leukocyte Function	https://ClinicalTrials.gov/show/NCT03027232	Completed	Beth Israel Deaconess Medical Center	2017-12-15
NCT02983318	Molecular Imaging of Brain Inflammation in Depressive Disorders	https://ClinicalTrials.gov/show/NCT02983318	Completed	Lawson Health Research Institute	2019-03-20
NCT02979951	Fosfomycin i.v. for Treatment of Severely Infected Patients	https://ClinicalTrials.gov/show/NCT02979951	Recruiting	Infectopharm Arzneimittel GmbH	2020-06-30
NCT02933710	Postmarketing Surveillance Study for IMOJEV® in Republic of Korea	https://ClinicalTrials.gov/show/NCT02933710	Completed	Sanofi	2018-10-18
NCT02906631	Epidemiology and Prognosis of Encephalitis in Intensive Care	https://ClinicalTrials.gov/show/NCT02906631	Recruiting	Assistance Publique - Hôpitaux de Paris	2021-07-31
NCT02905136	Mechanisms of Auto-immune Encephalitis	https://ClinicalTrials.gov/show/NCT02905136	Active, not recruiting	Hospices Civils de Lyon	2018-09-30
NCT02802475	Antibodies Causing Epilepsy Syndromes: The ACES Study.	https://ClinicalTrials.gov/show/NCT02802475	Recruiting	Erasmus Medical Center	2019-01-31
NCT04339205	Diffusion Imaging in Acute Auto-immune Encephalitis	https://ClinicalTrials.gov/show/NCT04339205	Recruiting	Hospices Civils de Lyon	2020-03-01
NCT01851356	Brain Inflammation in Major Depressive Disorder Background	https://ClinicalTrials.gov/show/NCT01851356	Completed	National Institutes of Health Clinical Center (CC)	2017-07-27
NCT01694524	Nervous System Infections Among Patients With Febrile Seizure	https://ClinicalTrials.gov/show/NCT01694524	Completed	Hôpital Armand Trousseau	2014-03-31
NCT01335412	Safety Surveillance After Immunization With IXIARO	https://ClinicalTrials.gov/show/NCT01335412	Completed	Valneva Austria GmbH	2013-06-30
NCT04339127	Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis	https://ClinicalTrials.gov/show/NCT04339127	Recruiting	Hospices Civils de Lyon	2020-06-01
NCT03958058	Tick-borne Encephalitis and Possible Borrelial Serology	https://ClinicalTrials.gov/show/NCT03958058	Completed	University Medical Centre Ljubljana	2013-12-31
NCT03856528	Infections of the Central Nervous System	https://ClinicalTrials.gov/show/NCT03856528	Completed	University Hospital, Basel, Switzerland	2019-09-01
NCT03710278	The Effectiveness and Safety of Human Lumbar Puncture Assist Device (LPat)	https://ClinicalTrials.gov/show/NCT03710278	Completed	Spartanburg Regional Healthcare System	2019-01-23
NCT03530462	To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI	https://ClinicalTrials.gov/show/NCT03530462	Completed	First Affiliated Hospital of Zhejiang University	2018-02-28
NCT03872284	Neuro-ophthalmology and Autoimmune Encephalitis (NODE)	https://ClinicalTrials.gov/show/NCT03872284	Recruiting	Hospices Civils de Lyon	2027-01-24
NCT02856451	Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab	https://ClinicalTrials.gov/show/NCT02856451	Active, not recruiting	Bristol-Myers Squibb	2021-12-31
NCT03932448	Fever After Tick Bite Study	https://ClinicalTrials.gov/show/NCT03932448	Recruiting	Göteborg University	2022-12-20
NCT00596102	Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51	https://ClinicalTrials.gov/show/NCT00596102	Completed	Valneva Austria GmbH	2011-03-31
NCT00163618	Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children	https://ClinicalTrials.gov/show/NCT00163618	Completed	Pfizer	NA
NCT00069303	Natural History of West Nile Virus Infection	https://ClinicalTrials.gov/show/NCT00069303	Completed	National Institutes of Health Clinical Center (CC)	NA
NCT00001648	Structure of the Herpes Simplex Virus Receptor	https://ClinicalTrials.gov/show/NCT00001648	Completed	National Institutes of Health Clinical Center (CC)	NA

Registries

#If less then 500 registries

nct_id	brief_title	link	overall_status	source	primary_completion_date
NCT03206541	Neurologic Manifestations of the Arbovirus Infection in Colombia	https://ClinicalTrials.gov/show/NCT03206541	Completed	Johns Hopkins University	2019-12-31
NCT04089436	SouthEast Asia Encephalitis Project	https://ClinicalTrials.gov/show/NCT04089436	Active, not recruiting	Institut Pasteur	2019-09-30